Navigation Links
Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
Date:6/27/2011

THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company presented clinical data from a mechanistic study of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), in patients with type 2 diabetes at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, California.  In addition, the company announced that it has commenced enrollment of patients with type 2 diabetes in its Phase 2b clinical trial of LX4211.

Data from the mechanistic study demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  For more information on this program or to download a copy of the poster from the ADA meeting, please visit www.lexpharma.com.

The Phase 2b trial is a randomized, double-blind, placebo controlled study of LX4211 in approximately 285 adult patients (18-75 years) with type 2 diabetes who are not adequately controlled on metformin monotherapy.  Patients will be administered LX4211 in combination with standard metformin therapy over 12 weeks.  Doses will include 75 mg once daily, 200 mg once daily, 200 mg twice daily, 400 mg once daily or placebo.  The primary endpoint of the study is the change from baseline in HbA1c at Week 12.  Secondary endpoints will include percentage of patients achieving HbA1c < 7%, and changes in fasting plasma glucose, 3-hour glucose tolerance test, weight, blood pressure, and triglycerides.  The study will be conducted at ap
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and MENLO PARK, Calif. , July ... DMPI) ("DelMar" "the company") announced today that the company,s board ... from December 31 to June 30. Accordingly, DelMar will file ... Jeffrey Bacha , president and CEO of ... important step in achieving our goal of obtaining a senior ...
(Date:7/24/2014)... ATLANTA , July 24, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... release its second quarter of fiscal year 2014 financial ... 2014. An investor conference call will follow on the ... The conference call will be hosted by Dan ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Alimera Sciences To Release Second Quarter 2014 Results 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... 2011 Bacterin International Holdings, Inc. (NYSE ... developer of revolutionary bone graft material and anti-microbial coatings ... first quarter ended March 31, 2011.  Since the beginning ... the number of medical facilities in which its products ...
... Technologies Inc. (OTCBB: MDCE), a children,s healthcare service ... children,s health and wellness center. The City of Dongguan ... of choice to establish the Company,s first flagship pediatric ... chosen because of its progressive economics, recording 10.3% GDP ...
Cached Medicine Technology:Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 2Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 3Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 4Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 5Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 6Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 7Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 8Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 9Medical Care Technologies Inc. Selects Geographical Location for Flagship Children's Health Center 2Medical Care Technologies Inc. Selects Geographical Location for Flagship Children's Health Center 3
(Date:7/25/2014)... Las Vegas, NV (PRWEB) July 25, 2014 ... hosting the one day Online Workshop ‘Consciousness is Power’ ... the globe are invited to attend this life transforming ... their consciousness to a higher level. Few days are ... During this workshop, Mahendra Trivedi and Trivedi Masters™ Dahryn ...
(Date:7/25/2014)... Fort Myers, FL (PRWEB) July 25, 2014 ... Apple iPhones, iPods, and iPads. The app provides a ... preventing painful and potentially dangerous sunburns and skin damage. ... about the sights, sounds, and capabilities of iTanSmart. ... by describing the app as a ‘better organized’ and ...
(Date:7/25/2014)... Silver®Care , for the first time in the United ... kill oral bacteria and airborne bacteria from the bathroom that ... the most common and important device in the prevention of ... to constant contamination by bacteria found in the mouth and ... mouth than anywhere else in the human body, and some ...
(Date:7/24/2014)... 2014 A few weeks have passed ... incredible high jump by Inika McPherson is a feat ... the USATF National Championships hosted the best track and ... McPherson, won US Nationals with the 2nd best jump ... for the biggest height over head jump in history. ...
(Date:7/24/2014)... Voted one of the most reliable online dress suppliers ... providing its new and old customers with the latest ... announced its new collection of high end wedding dresses. ... to the latest fashion trends. Additionally, they are now ... As a matter of fact, high end special occasion ...
Breaking Medicine News(10 mins):Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2
... must pass legislation to give FDA needed regulatory ... The following is a,statement by Ron Davis, M.D., ... the U.S. House of Representatives must take a ... ,Family Smoking and,Tobacco Control Act, and giving the ...
... The Los Angeles Jewish Home,s,prestigious new Annenberg School ... second session as one of the only U.S. multi-level,senior-living ... Annenberg School of Nursing offers a full-time program that ... licensure. The,intensive vocational nursing program engages students 40 hours ...
... Researchers at the University of Minnesota have found that cerebral malaria ... survivors. The research is published in the current issue of the ... Malaria is a leading cause ... affects more than 750,000 children a year, is one of the ...
... Available For International Licensing, LAS VEGAS, ... SKVI)( http://www.skinvisible.com, , http://www.invisicare.com ), the developers ... enhances topical skincare products, announces,the successful development ... the,active ingredient avobenzone (Parsol(R) 1789) with Invisicare. ...
... Applauds Chance to Make a Difference, ROSEMONT, Ill., ... Convention confirmed today that the $25,000,offer to Steve Bartman ... online polls, the public says he should appear., ... 3 at the Donald E.,Stephens Convention Center in Rosemont, ...
... allergies such as asthma and hay fever might enjoy a ... New South Wales (UNSW). , In a paper presented at ... with one of these atopic diseases are up to 25 ... Non-Hodgkin Lymphoma (NHL). , The InterLymph Symposium is co-hosted by ...
Cached Medicine News:Health News:Los Angeles Jewish Home's New Annenberg School of Nursing Seeks Applicants for Second Session of Precedent-Setting U.S. Senior-Care Facility's School of Nursing 2Health News:Los Angeles Jewish Home's New Annenberg School of Nursing Seeks Applicants for Second Session of Precedent-Setting U.S. Senior-Care Facility's School of Nursing 3Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:Skinvisible Offers 8 Hour Photostablity for Parsol 1789 2Health News:Skinvisible Offers 8 Hour Photostablity for Parsol 1789 3Health News:Fans Encourage Steve Bartman to Accept $25,000 Autograph Offer 2Health News:Hey fever! The surprise benefit of allergies 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
Medicine Products: